Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

News Conference News AHA 2024

Lipid Fluctuations Over Time May Portend Dementia: ASPREE

Yael L. Maxwell

November 15, 2024

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

November 17, 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

November 17, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

News Conference News AHA 2020

Fish Oil, Vitamin D Don’t Prevent A-fib: VITAL Rhythm

November 13, 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

News Conference News AHA 2020

SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults

November 13, 2020

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

News Conference News AHA 2018

Post-MI Yoga: Randomized Trial Shows Feasibility and Safety as an Option for Cardiac Rehab

Yael L. Maxwell

November 10, 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2015

CANOA: Fewer Migraines With Clopidogrel Plus Aspirin Post-ASD Closure

November 08, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.